

The Board of Pharmacy has received notice of the following product recall:

LEVEL OF NOTIFICATION: Retail

SUPPLIER: Lannett

Description	Lot #/Exp Date	NDC	UPC
RANITID OS 75MG/5ML SILA 16OZ@	1795A 06/01/20; 1729A 04/01/20;	54838055080	35483855080
	1730A 04/01/20; 1731A 04/01/20;		
	1757A 05/01/20; 1758A 05/01/20;		
	1759A 05/01/20; 1773A 06/01/20;		
	1774A 06/01/20; 1864A 09/01/20;		
	1794A 06/01/20; 1708A 03/01/20;		
	1796A 06/01/20; 1817A 06/01/20;		
	1818A 07/01/20; 1819A 07/01/20;		
	1840A 08/01/20; 1840B 08/01/20;		
	1841A 08/01/20; 1842A 08/01/20;		
	1503A 10/01/19; 1775A 06/01/20;		
	1614A 01/01/20; 1504A 10/01/19;		
	1505A 10/01/19; 1523A 10/01/19;		
	1524A 10/01/19; 1525A 11/01/19;		
	1561A 12/01/19; 1562A 12/01/19;		
	1563A 12/01/19; 1589A 12/01/19;		
	1710A 04/01/20; 1591A 12/01/19;		
	1709A 04/01/20; 1615A 01/01/20;		
	1617A 01/01/20; 1644A 02/01/20;		
	1646A 02/01/20; 1647A 02/01/20;		
1668A 03/01/20; 1669A 03/01/20;			

Description	Lot #/Exp Date	NDC	UPC
	1670A 03/01/20; 1865A 09/01/20; 1590A 12/01/19; 2127A 05/01/21; 2065A 03/01/21; 2066A 03/01/21; 2067A 03/01/21; 2071A 03/01/21; 2072A 03/01/21; 2073A 03/01/21; 2076A 03/01/21; 2077A 03/01/21; 1863A 08/01/20; 2126A 05/01/21; 2000A 01/01/21; 2128A 05/01/21; 2164A 06/01/21; 2165A 06/01/21; 2166A 06/01/21; 2179A 06/01/21; 2180A 07/01/21; 2181A 07/01/21; 2214A 08/01/21; 2215A 08/01/21; 2078A 03/01/21; 1927A 10/01/20; 1899A 10/01/20; 1900A 10/01/20; 1901A 10/01/20; 1910A 10/01/20; 1911A 10/01/20; 1912A 10/01/20; 1918A 10/01/20; 1919A 10/01/20; 1920A 10/01/20; 2020A 01/01/21; 1926A 10/01/20; 2019A 01/01/21; 1977A 12/01/20; 1978A 12/01/20; 1979A 12/01/20; 1989A 12/01/20; 1990A 12/01/20; 1991A 12/01/20; 1998A 01/01/21; 1999A 01/01/21; 2216A 08/01/21; 1925A 10/01/20		

Lannett is recalling the above lots of this Ranitidine Syrup due to the presence of a potential carcinogen within products. This recall is to the retail level, NOT CONSUMER LEVEL. Affected product includes all unexpired lots as listed above.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.